Therapeutic perspectives of linezolid in the management of infections due to multiresistant gram-positive pathogens;Le prospettive terapeutiche di linezolid nelle infezioni da patogeni gram-positivi multiresistenti

Recenti Progressi in Medicina

Volumn 98, Issue 3, 2007, Pages 143-154

  Manfredi, Roberto ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Enterococci; Linezolid; Oxazolidinones; Resistant Gram positive organisms; Staphylococci

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GLYCOPEPTIDE; LINEZOLID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE;

ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL FEATURE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; GRAM POSITIVE BACTERIUM; HUMAN; REVIEW; STAPHYLOCOCCUS INFECTION;

ACETAMIDES; ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INJECTIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; OXAZOLIDINONES; PRACTICE GUIDELINES; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TEICOPLANIN; TIME FACTORS; VANCOMYCIN; VIRGINIAMYCIN;

EID: 34247357774     PISSN: 00341193     EISSN: 00341193     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Karchmer AW. Nosocomial bloodstream infections: organisms, risk factors, and implications. Clin Infect Dis 2000: 31 (suppl 4): S139-43.
2. Stevens DL, Dotter B, Madaras-Kelly A. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti-Infective Ther 2004; 2: 51-9.
3. Cunha BA. Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy. Clin Microbiol Infect 2005; 11 (suppl 4): 33-42.
4. Kollef MH. Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection. Eur J Clin Microbiol Infect Dis 2005; 24: 794-803.
5. Menichetti F. Current and emerging serious Gram-positive infections. Clin Microbiol Infect 2005; 11 (suppl 3): 22-8.
6. Wenzel RP, Edmond MB. Vancomycin-resistant Staphylococcus aureus: infection control considerations. Clin Infect Dis 1998; 27: 245-9.
7. Linden PK. Treatment options for vancomycin-resistant enterococcal infections. Drugs 2002; 62: 425-41.
8. Segreti J. Efficacy of current agents used in the treatment of Gram-positive infections and the consequences of resistance. Clin Microbiol Infect 2005; 11 (suppl 3): 29-35.
9. Pace JL, Yang G. Glycopeptides: update on an old successful antibiotic class. Biochem Pharmacol 2006; 71: 968-80.
10. Ladhani S, Garbash M. Staphylococcal skin infections in children: rational drug therapy recommendations. Paediatr Drugs 2005: 7: 77-102.
11. Marcinak JF, Frank AL. Epidemiology and treatment of community-associated methicillin-resistant Staphylococcus aureus in children. Expert Rev Anti Infect Ther 2006; 4: 91-100.
12. nd. Treatment approaches for community-acquired methicillin-resistant Staphylococcus aureus infections. Curr Opin Infect Dis 2005; 18: 496-501.
13. Edmond MB Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals. A three-year analysis. Clin Infect Dis 1999; 29: 239-44.
14. Manfredi R, Nanetti A, Morelli S, Valentini R, Calza L, Chiodo F. Sensitivity of methicillin-resistant Staphylococcus aureus (MRSA) to antimicrobial agents other than beta-lactams: profile and trend, 1998-2003. Isr Med Assoc J 2004; 6: 191-2.
15. Cuevas O, Cercenado E, Vindel A, et al. Evolution of antimicrobial resistance of Staphylococcus spp. In Spain: five nationwide prevalence studies, 1986 to 2002. Antimicrob Agents Chemother 2004; 48: 4240-5.
16. Hsueh PR, Chen WH, Teng LJ, Luh KT. Nosocomial infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a University Hospital in Taiwan from 1991 to 2003: resistance trends, antibiotic usage and in vitro activities of newer antimicrobial agents. Int J Antimicrob Agents 2005; 26: 43-9.
17. Lamb HM, Figgitt DP, Faulds D. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs 1999; 58: 1061-97.
18. Akins RL, Haase KK.Gram-positive resistance: pathogens, implications, and treatment options: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2005; 25: 1001-10.
19. Nicoletti G, Bonfiglio G, Bartoloni A, et al. Distribution and antibiotic resistance of isolates from lower respiratory tract and blood cultures from patients in three Italian intensive care units: a 2-year comparison. Int J Antimicrob Agents 2000; 15: 265-9.
20. Marshall SA, Wilke WW, Pfaller MA, Jones EN. Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE program. Diagn Microbiol Infect Dis 1998; 30: 205-14.
21. Anonymous. Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan 1996. MMWR 1997; 46: 624-6.
22. Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis 2004; 38: 17-24.
23. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002; 346: 867-9.
24. Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004; 39: 1010-5.
25. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49: 2260-6.
26. Eliopoulos GM. Quinupristin/dalfopristin and linezolid: evidence and opinions. Clin Infect Dis 2003; 36: 473-81.
27. Moellering RC Jr. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138: 135-42.
28. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003; 36: 159-68.
29. Anderegg TR, Sader HS, Fritsche TR, Ross JE, Jones RN. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox annual appraisal of potency and spectrum (ZAAPS) program. Int J Antimicrob Agents 2005; 26: 13-21.
30. Jones RN, Ross JE, Fritsche TR, Sader HS. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox annual appraisal of potency and spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 2006; 57: 279-87.
31. Sharpe JN, Shively EH, Polk HC Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower extremity skin and soft tissue infections caused by methicillin-resistant Staphyloccus aureus. Am J Surg 2005; 189: 425-8.
32. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind multicenter study. Clin Infect Dis 2001; 32: 402-12.
33. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003; 25: 980-92.
34. Wilcox M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J Antimicrob Chemother 2004; 53: 335-42.
35. Nathwani D, Li JZ, Balan DA, et al. An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects. Int J Antimicrob Agents 2004; 23: 315-24.
36. Craven DE, Palladino R, McQuillen DP. Healthcare-associated pneumonia in adults: management principles to improve outcomes. Infect Dis Clin North Am 2004; 18: 939-62.
37. Hill EE, Herijgers P, Herregods MC, Peetermans WE. Infective endocarditis treated with linezolid: case report and literature review. Eur J Clin Microbiol Infect Dis 2006; 25: 202-4.
38. Castro P, Soriano A, Eschrich C, Villalba G. Sarasa M, Mensa J. Linezolid treatment of ventriculoperitoneal shunt infection without implant removal. Eur J Clin Microbiol Infect Dis 2005; 24: 603-6.
39. Sabbatani S, Manfredi R, Frank G, Chiodo F. Linezolid in the treatment of central nervous system infections resistant to recommended antimicrobial compounds. Infez Med 2005; 13: 112-9.
40. Manfredi R, Sabbatani S, Marinacci G, Salizzoni E, Chiodo F. Listeria monocytogenes meningitis and multiple brain abscesses in an immunocompetent host. Favorable response to combined linezolid treatment. J Chemother 2006; 18: 331-3.
41. Manfredi R, Sabbatani S, Chiodo F. Severe staphylococcal knee arthritis responding favourably to linezolid, after glycopeptide-rifampicin failure: a case report and literature review. Scand J Infect Dis 2005; 37: 513-7.
42. Barberan J. Management of infections of osteoarticular prosthesis. Clin Microbiol Infect 2006; 12 (suppl 3): 93-101.
43. Alcala L, Ruiz-Serrano MJ, Pérez-Fernandez-Turégano C, et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother 2003; 47: 416-7.
44. Erturan Z, Uzun M. In vitro activity of linezolid against multidrug-resistant Mycobacterium tuberculosis isolates. Int J Antimicrob Agents 2005; 26: 78-80.
45. Fortun J, Martin-Davilla P, Navas E, et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005; 56: 180-5.
46. Rodriguez Diaz JC, Ruiz M, Lopez M, Royo G. Synergistic activity of fluoroquinolones and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2003; 21: 354-6.
47. Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004; 4: 528-31.
48. Nasraway SA, Shorr AF, Kuter DJ, O'Grady N, Le VH, Cammarata SK. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis 2003; 37: 1609-16.
49. Kopterides P, Papadomichelakis E, Armaganidis A. Linezolid use associated with lactic acidosis. Scand J Infect Dis 2005; 37: 153-4.
50. Salyers AA, Gupta A, Wang Y. Human intestinal bacteria as reservoirs for antibiotic resistance genes. Trends Microbiol 2004; 12: 412-6.
51. Fiaccadori E, Maggiore U, Rotelli C, et al. Removal of linezolid by conventional intermittent hemodyalisis, sustained low-efficiency dyalisis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med 2004; 32: 2437-42.
52. Clark DB, Andrus MR, Byrd DC. Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature. Pharmacotherapy 2006; 26: 269-76.
53. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity with the use of linezolid: a review of postmarketing data. Clin Infect Dis 2006; 42: 1578-83.
54. Sola CL, Bostwick JM, Hart DA, Lineberry TW. Anticipating potential linezolid-SSRI interactions in the general hospital setting: an MAOI in disguise. Mayo Clin Proc 2006; 81: 330-4.
55. Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled Phase III studies. Antimicrob Agents Chemother 2003; 47: 1824-31.
56. Abbanat D, Macielag M, Bush K. Novel antibacterial agents for the treatment of serious Gram-positive infections. Expert Opin Investig Drugs 2003; 12: 379-99.
57. Hancock RE. Mechanism of action of newer antibiotics for Gram-positive pathogens. Lancet Infect Dis 2005; 5: 209-18.
58. Manfredi R. A re-emerging class of antimicrobial agents: streptogramins (quinupristin/dalfopristin) in the management of multiresistant gram-positive nosocomial cocci in hospital setting. Mini Rev Med Chem 2005; 5: 1075-81.
59. Smith PF, Booker BM, Ogundele AB, Kelchin P. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center. Diagn Microbiol Infect Dis 2005; 52: 255-9.
60. Garcia-Roca P, Mancilla-Ramirez J, Santos-Segura A, Fernandez- Avilés M, Calderon-Jaimes E. Linezolid diminishes inflammatory cytokine production from human peripheral blood mononuclear cells. Arch Med Res 2006; 37: 31-5.
61. Shah PM. The need for new therapeutic agents: what is the pipeline? Clin Microbiol Infect 2005; 11 (suppl 3): 36-42.
62. Schmidt-Ioanas M, De Roux A, Lode H. New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient. Curr Opin Crit Care 2005; 11: 481-6.
63. Tsuji BT, Rybak MJ. Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin. Diagn Microbiol Infect Dis 2006; 54: 73-7.